Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS.

J Clin Invest. 2014 Jun;124(6):2611-25. doi: 10.1172/JCI69815. Epub 2014 Apr 24.

2.

Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.

Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R.

Oncogene. 2015 Jan 15;34(3):373-83. doi: 10.1038/onc.2013.562. Epub 2014 Jan 27.

3.

In vitro mesothelial clearance assay that models the early steps of ovarian cancer metastasis.

Davidowitz RA, Iwanicki MP, Brugge JS.

J Vis Exp. 2012 Feb 17;(60). pii: 3888. doi: 10.3791/3888.

4.

Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.

Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Brugge JS.

Cancer Discov. 2011 Jul;1(2):144-57. doi: 10.1158/2159-8274.CD-11-0010. Erratum in: Cancer Discov. 2011 Dec;1(7):626. Ince, Tan [corrected to Ince, Tan A].

Supplemental Content

Loading ...
Support Center